Onco Actu du 22 février 2017

	4. Dépistage, diagnostic et pronostic
Can Craig Venter Cheat Death? [Forbes] Venter believes the problem with earlier screening tests is that they give too little data, not too much. He is his own evidence. He was the first person to get his DNA sequenced, and the results made him think his risk for most types of cancer was low. When he got prostate cancer, he asked his researchers why. They found what he calls "the likely perpetrator."
	4.10 Dép., diag. & prono. - FDA, EMA, NICE,...
Is the United States Preventive Services Task Force still a voice of caution? [BMJ] Recent recommendations issued by the USPSTF have surprised some experts who say they may lead to overtesting and overtreatment.
	4.10 Dép., diag. & prono. - Poumon
We Can Find Lung Cancer Early And Save Lives, So Why Aren’t More Smokers And Former Smokers Getting Screened? [Dr. Len] The reasons may be many, among them that health professionals either aren’t aware of the recommendations and insurance coverage or may be a bit skeptical (health professional behaviors are frequently slow to change).
	4.5 Dép., diag. & prono. - Colorectal
One-off bowel scope cuts cancer risk for at least 17 years [Cancer Research UK] The team followed more than 170,000 people for 17 years on average and more than 40,000 had the bowel scope test. It is the longest study ever done on the effectiveness of the test.
New screening test cuts bowel cancer risk by a third, study finds [The Guardian] The test, which is being rolled out across England, will invite men and women to have bowel scope screening around the time of their 55th birthday. This is in addition to the current test from the age of 60, the faecal occult blood test (FOB), which is posted to people’s homes.
	4.9 Dép., diag. & prono. - Sein
Screening MRI Benefits Women at Average Risk of Breast Cancer [RSNA] Researchers studied data from 2,120 women with no breast-cancer-associated risk factors who underwent supplemental MRI screening every 1 to 3 years in addition to mammography and ultrasound.
	5.10 Traitements - Essais
TAPUR Trial Expands Who Can Join Clinical Trials, If Payers Fund Genomic Tests [AJMC] As TAPUR expands to 63 participating sites by the end of 2016, Mangat emphasized that the study is “test agnostic,” meaning it doesn’t prefer a single manufacturer, and that it will use earlier tests instead of requiring a fresh biopsy when a patient is screened for the study.
Phase II Study Supports Potential for Atezolizumab plus Bevacizumab for Locally Advanced or Metastatic Renal Cell Carcinoma [ESMO] Hypothesis generating study in first line mRCC shows that two drugs can be combined with a manageable safety profile and encouraging efficacy.
	5.12 Immunothérapies
FDA’s Pazdur and Blumenthal: The March of Checkpoint Inhibitors Will Continue [RAPS] “Short-term and longer-term FDA oncology priorities include the use of ‘real-world evidence’ (RWE) to enable evidence generation outside of clinical trials.”
	5.12.5 Immunothérapies - Pharma
Lead cancer immunotherapy candidate receives FDA fast track designation [Cell Medica] CMD-003, also known as baltaleucel-T, is an investigational therapy in which the patient’s T cells are activated to kill malignant cells expressing EBV antigens. The product has the potential to address a range of EBV-associated lymphomas, nasopharyngeal carcinoma and gastric cancer.
	5.2 Pharma
FDA accepts Pfizer’s blood cancer candidate for speedy review [FierceBiotech] Pfizer's latest breakthrough-designated drug, which is also being looked at by the EMA in Europe, has seen its submissions based on the phase 3 INO-VATE 1022 trial, which looked at relapsed or refractory B-cell ALL and compared inotuzumab ozogamicin to standard-of-care chemo.
VBL posts additional data from phase 2 thyroid cancer trial [FierceBiotech] In the latest release, VBL reported eight of the 17 patients in the high-dose cohort went six months or more without progressing, compared to six of 17 in previous publications.
Pfizer Announces Acceptance of Regulatory Submission for Inotuzumab Ozogamicin by the U.S. Food and Drug Administration [Pfizer] Application Requests Approval for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia in Adults.
Pfizer shortens comeback campaign for armed antibody inotuzumab, lands quick FDA review [EndPoints] The news marks the latest comeback advance for the antibody-drug conjugate, which flopped in a Phase III trial for non-Hodgkin’s lymphoma four years ago, badly tarnishing the prospects for a drug that had been touted as a top contender by CEO Ian Read.
	5.2.2 Pharma - Fusions & Acquisitions
Buyout buzz swells for the giant Bristol-Myers after Carl Icahn makes an entrance, stage left [EndPoints] Carl Icahn, the aging activist who’s prodded a series of high-profile biopharma companies into the arms of eager buyers, has taken a stake in the highly stressed Bristol-Myers Squibb, building speculation that the troubled giant could be in line for a buyout – as improbable as that may sound to many.
	5.2.3 Pharma - économie
AstraZeneca's latest Kondo-izing move: A $250M-plus deal for cancer med Zoladex [FiercePharma] AstraZeneca is offloading yet another set of drug rights to streamline its portfolio and raise some cash. The U.K.-based drugmaker has agreed to hand over its cancer drug Zoladex in the U.S. and Canada to TerSera Therapeutics in a $250 million-plus deal.
	5.4 Traitements - Economie
NICE draft guidelines reject Ipsen’s Cabometyx [PharmaTimes] NICE's independent appraisal committee concluded that the additional benefits of the drug, when compared with current care, "were highly uncertain as the meta-analysis evidence presented by the company was unreliable," a NICE spokesperson said.
	5.5.4 ASCO (immunothérapies)
Utility of Biomarkers for Predicting Colorectal Cancer Survival Depends on Tumor Location [ASCO] A large population-based study suggests that the utility of certain types of biomarkers, known as tumor-infiltrating lymphocytes (TILs), to predict colorectal cancer survival depends on where the tumor originates in the body.
Response to Cancer Immunotherapy May Depend on Gut Bacteria [ASCO] In the study, the ability of patients with advanced melanoma to respond to PD-1 immune checkpoint inhibitors depended on the presence of a diverse microbiome as well as specific bacterial species. The study will be presented at the upcoming 2017 ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando.
	6.1 Observation
Annals of Oncology Press Release: Death Rates from Cancer will Fall Faster in Men than in Women in Europe in 2017 [ESMO] “Overall, fewer women than men will die from cancer, but the fact that the rate of decline is slower in women than in men essentially reflects the different trends in lung and other tobacco-related cancers between the two sexes.”
U.S. Cancer Mortality Rates Falling, But Some Regions Left Behind, Study Finds [NCI] Rates of death from cancer in the United States dropped by 20% between 1980 and 2014, according to new research from the Institute for Health Metrics and Evaluation at the University of Washington.
Life expectancy study shows many likely to live beyond 90 by 2030 [Reuters] In Europe, French women and Swiss men were predicted to have the highest life expectancies, averaging 88.6 years for French women and nearly 84 years for Swiss men.
	6.10 Politiques
China biotech makes big data a weapon in its war on cancer [China Daily] China has made the precision medicine field a focus of its 13th Five-Year Plan (2016-20), and its companies have been embarking on ambitious efforts to collect a vast trove of genetic and health data, researching how to identify cancer markers in blood, and launching consumer technologies that aim to tap potentially lifesaving information.
	6.11 Patients
The real quest of cancer treatment: dispensing the right mix of hope and reality [The Guardian] So many advances in cancer, so many protocols, but still missing is the protocol that says, dispense just this much fact, mix just so much optimism, offer precisely this much warning, infuse just so much hope and things will turn out fine.
Steve Hewlett’s legacy could be to save lives by raising cancer awareness [The Guardian] Everyone who heard Steve Hewlett’s moving account of his oesophageal cancer will be sad to know that, for him, there was no cure. But I write as the wife of a survivor of this disease. My husband, now 81, was diagnosed in November 2011.
	6.6 Publications
No publication without confirmation [Nature] Our proposal is a new type of paper for animal studies of disease therapies or preventions: one that incorporates an independent, statistically rigorous confirmation of a researcher's central hypothesis.
Got “significosis?” Here are the five diseases of academic publishing [Retraction Watch] These diseases, which are strongly interlinked and probably have overlapping causes, include: Significosis, Neophilia, Theorrhea, Arigorium and Disjunctivitis.
	6.7 DMP, Big Data & applis
Computer algorithm predicts outcome for leukemia patients [Stanford Medicine] The research team trained their computer algorithm using bone marrow data and medical histories of AML patients along with blood data from healthy individuals. They then tested the algorithm using data collected from 36 additional AML patients.